Country: Canada
Language: English
Source: Health Canada
AMITRIPTYLINE HYDROCHLORIDE
PHARMASCIENCE INC
N06AA09
AMITRIPTYLINE
25MG
TABLET
AMITRIPTYLINE HYDROCHLORIDE 25MG
ORAL
100/1000
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0101524002; AHFS:
APPROVED
1998-12-11
_pms-AMITRIPTYLINE (amitriptyline chlorhydrate) _ _Page 1 of 44 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PMS-AMITRIPTYLINE Amitriptyline Hydrochloride Tablets Tablets, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, Oral USP Antidepressant PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 www.pharmascience.com Submission Control Number: 277374 Date of Initial Authorization: December 11, 1998 Date of Revision: January 5, 2024 _pms-AMITRIPTYLINE (amitriptyline chlorhydrate) _ _Page 2 of 44 _ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 01/2024 7 WARNINGS AND PRECAUTIONS 01/2024 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 01/2024 7 WARNINGS AND PRECAUTIONS, Neurologic 02/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................................... 2 TABLE OF CONTENTS ....................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................... 4 1 INDICATIONS ............................................................................................................................. 4 1.1 Pediatrics ................................................................................................................................. 4 1.2 Geriatrics .................................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................................... 5 4 DOSAGE AND ADMINISTRATION .............................................................................. Read the complete document